The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.

The invention relates to a liquid-crystalline medium which comprises at least one compound of the formula I, ##STR00001##
in which R.sup.1, R.sup.1*, Z.sup.1, Z.sup.2 and L.sup.1-3 have the meanings defined herein, and to the use thereof for an active-matrix display, in particular based on the VA, PSA, PS-VA, PALC, FFS, PS-FFS, PS-IPS or IPS effect.

The invention relates to a liquid-crystalline medium which comprises at least one compound of the formula I, ##STR00001##
in which R.sup.1, R.sup.1*, Z.sup.1, Z.sup.2 and L.sup.1-3 have the meanings defined herein, and to the use thereof for an active-matrix display, in particular based on the VA, PSA, PS-VA, PALC, FFS, PS-FFS, PS-IPS or IPS effect.

The invention relates to a liquid-crystalline medium which comprises at least one compound of the formula I, ##STR00001##
in which
R.sup.1, R.sup.1*, Z.sup.1, Z.sup.2 and L.sup.1-3 have the meanings defined herein,
and to the use thereof for an active-matrix display, in particular based on the VA, PSA, PS-VA, PALC, FFS, PS-FFS, PS-IPS or IPS effect.

The invention relates to a liquid-crystalline medium which comprises at least one compound of the formula I, ##STR00001##
in which
R.sup.1, R.sup.1*, Z.sup.1, Z.sup.2 and L.sup.1-3 have the meanings defined herein,
and to the use thereof for an active-matrix display, in particular based on the VA, PSA, PS-VA, PALC, FFS, PS-FFS, PS-IPS or IPS effect.

The invention relates to a liquid-crystalline medium which comprises at least one compound of the formula I, ##STR00001## in which R.sup.1, R.sup.1*, Z.sup.1, Z.sup.2 and L.sup.1-3 have the meanings defined herein, and to the use thereof for an active-matrix display, in particular based on the VA, PSA, PS-VA, PALC, FFS, PS-FFS, PS-IPS or IPS effect.

The invention relates to a liquid-crystalline medium which comprises at least one compound of the formula I, ##STR00001## in which R.sup.1, R.sup.1*, Z.sup.1, Z.sup.2 and L.sup.1-3 have the meanings defined herein, and to the use thereof for an active-matrix display, in particular based on the VA, PSA, PS-VA, PALC, FFS, PS-FFS, PS-IPS or IPS effect.

This invention is in the field of medicinal pharmacology. In particular, the present invention relates to pharmaceutical agents which function as inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral replication and/or SARS-CoV-2 related viral 3CL protease (M.sup.pro) activity, which function as therapeutics for the treatment of conditions caused by the SARS-CoV-2 virus (e.g., COVID-19), and which function as therapeutics for the treatment conditions related to SARS-CoV-2 related M.sup.pro activity.

Provided are compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, e.g., those involving ferroptosis.

##STR00001##

Provided are compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, e.g., those involving ferroptosis.

##STR00001##